pharma · Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) · Advanced Solid Tumor
Daiichi Sankyo US
Daiichi Sankyo
Daiichi Sankyo US clinical programs — 17 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 211 Mt. Airy Road Basking Ridge, Basking Ridge, NJ 07920, US
- Employees
- 4,386
- Programs
- 58
- Drugs
- 66
- Patents
- 0
Daiichi Sankyo US projects
17 ClinicalTrials.gov programs sponsored by Daiichi Sankyo US.
Daiichi Sankyo US has 17 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
DS-1205c
Daiichi Sankyo
Non-small Cell Lung Cancer (NSCLC)
1 trial -
DS1062-A-U102
Daiichi Sankyo
Non-small cell lung cancer
1 trial -
DS3201-324
Daiichi Sankyo
This study will be a Phase 1b, global, multicenter, open-label, 2-part study of valemetostat in combination with DXd ADCs. The Master Protocol study design contains independent subprotocols, which have been defined by treatment combination and subject population, as follows: Sub-protocol A: Valemetostat in combination with T-DXd in subjects with previously treated, unresectable and/or metastatic HER2-low (immunohistochemistry[IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) BC; for details, see Sub-protocol A. Sub-protocol B: Valemetostat in combination with T-DXd in subjects with previously treated, advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma; for details, see Sub-protocol B. Sub-protocol C: Valemetostat in combination with Dato-DXd in subjects with previously treated, locally advanced, unresectable, or metastatic non-squamous NSCLC with or without actionable genomic alteration(s); for details, see Sub-protocol C.
1 trial -
DS8201-A-U106
Daiichi Sankyo
Locally advanced/metastatic breast or non-small cell lung cancer
1 trial -
DSE-BMP-0001-CIS-MA
Daiichi Sankyo
No medical condition.
1 trial -
DSE-BMP-0002-CIS-MA
Daiichi Sankyo
No medical condition
1 trial -
DSE-BMP-0003-CIS-MA
Daiichi Sankyo
No medical condition.
1 trial -
DSE-BMP-0004-CIS-MA
Daiichi Sankyo
No medical condition.
1 trial -
First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors
Daiichi Sankyo
Advanced Solid Tumors
1 trial -
First-in-Human trial of DS9051b in participants with advanced solid tumors
Daiichi Sankyo
Advanced or Metastatic Adrenocortical Carcinoma (ACC), Metastatic Castration-resistant Prostate Cancer (CRPC)
1 trial -
First-in-human (FIH) Study of DS-1471a in Subjects with Advanced Solid Tumors
Daiichi Sankyo
Advanced Solid Tumors
1 trial -
First-in-human Trial of DS-2243a in Participants with Advanced Solid Tumors
Daiichi Sankyo
Advanced Solid Tumor
1 trial -
HER3-DXd
Daiichi Sankyo
Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Phase 1 trial of valemetostat and darolutamide in mCRPC
Daiichi Sankyo
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1 trial -
Study of U3-1402 in subjects with non-small cell lung cancer
Daiichi Sankyo
METASTATIC OR UNRESECTABLE NON-SMALL CELL LUNG CANCER
1 trial -
Subcutaneous Trastuzumab Deruxtecan Phase 1 Trial.
Daiichi Sankyo
Advanced Solid Tumor
1 trial -
Trastuzumab Deruxtecan
Daiichi Sankyo
Recurrent or Metastatic Solid Tumors
1 trial
Frequently asked questions
How many clinical projects does Daiichi Sankyo US have?
17 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.